MYOG and neoplasm: To target ARMS tumour cells, the human minimal MYOGENIN promoter was selected, since MYOGENIN is constitutively expressed in rhabdomyosarcoma cells, but only during myogenic differentiation in skeletal muscle myoblasts, and not in other cell types.